Protective Effects of GalNac-Modified Red Blood Cell-Derived Extracellular Vesicles Against Liver Diseases

Drug-loaded GalNac-RBC-EVs selectively targeted the hepatocytes, and displayed significant therapeutic efficacy in ALF, NAFLD or HCC without any side effects. Altogether, RBC-EVs modified with GalNac are a promising drug carrier for the effective and precise treatment of various liver diseases.